From: Association of serum Cyr61 levels with peripheral arterial disease in subjects with type 2 diabetes
Variables | All subjects (n = 306) | No PAD (n = 150) | Fontaine classification | P value for trend | ||
---|---|---|---|---|---|---|
II (n = 76) | III (n = 50) | IV (n = 30) | ||||
Male | 52.9 | 45.3 | 47.4 | 44.0 | 53.3 | 0.606 |
Age (years) | 61.2 ± 11.4 | 60.4 ± 12.0 | 59.2 ± 11.0 | 61.2 ± 11.0 | 62.6 ± 10.8 | 0.233 |
BMI (kg/m2) | 25.2 ± 3.3 | 25.1 ± 3.4 | 25.1 ± 3.4 | 25.0 ± 3.5 | 24.8 ± 3.3 | 0.640 |
Current smoker | 26.1 | 25.3 | 28.9 | 24.0 | 26.7 | 0.953 |
Hypertension | 51.0 | 48.0 | 52.6 | 56.0 | 53.3 | 0.344 |
Diabetes duration (years) | 8.6 ± 5.6 | 7.3 ± 6.1 | 9.6 ± 6.4 | 10.7 ± 6.0 | 12.8 ± 5.8 |  < 0.001 |
Total cholesterol (mmol/L) | 4.5 ± 1.3 | 4.6 ± 1.3 | 4.5 ± 1.3 | 4.7 ± 1.3 | 4.9 ± 1.1 | 0.172 |
TG (mmol/L) | 1.8 ± 1.5 | 1.9 ± 1.7 | 1.8 ± 1.5 | 1.7 ± 1.4 | 1.8 ± 1.7 | 0.692 |
HDL-C (mmol/L) | 1.2 ± 0.4 | 1.1 ± 0.4 | 1.2 ± 0.4 | 1.2 ± 0.4 | 1.3 ± 0.3 | 0.015 |
LDL-C (mmol/L) | 3.1 ± 0.7 | 3.1 ± 0.9 | 3.1 ± 0.7 | 3.1 ± 0.7 | 3.2 ± 0.8 | 0.557 |
HbA1c (%) | 8.8 ± 1.7 | 8.2 ± 1.5 | 8.9 ± 1.6 | 8.9 ± 1.5 | 9.1 ± 1.7 | 0.006 |
Fasting glucose (mmol/L) | 7.4 ± 1.6 | 7.1 ± 1.5 | 7.9 ± 1.7 | 7.7 ± 1.5 | 8.1 ± 1.5 | 0.004 |
eGFR (ml/min/1.73 m2) | 79.4 ± 8.4 | 82.3 ± 8.7 | 79.5 ± 8.9 | 78.5 ± 8.8 | 76.5 ± 8.4 |  < 0.001 |
Serum Cyr61 (pg/ml) | 219.1 ± 13.5 | 195.4 ± 11.9 | 221.0 ± 14.4 | 247.6 ± 11.8 | 275.5 ± 12.3 |  < 0.001 |
Use antidiabetes agents | ||||||
 Oral drugs | 58.2 | 61.3 | 60.5 | 48.0 | 55.3 | 0.225 |
 Insulin | 64.7 | 54.7 | 68.4 | 76.0 | 86.7 |  < 0.001 |
Use antihypertension agents | ||||||
 β-Blockers | 13.1 | 10.7 | 13.2 | 16.0 | 20.0 | 0.123 |
 Calcium-channel blockers | 24.2 | 24.0 | 23.7 | 24.0 | 26.7 | 0.826 |
 RAAS inhibitors | 47.1 | 40.0 | 47.4 | 56.0 | 66.7 | 0.003 |
 Diuretics | 6.5 | 5.3 | 7.9 | 8.0 | 6.7 | 0.551 |
Use lipid-lowering agents | ||||||
 Statins | 24.8 | 3221.3 | 2026.3 | 1428.0 | 1033.3 | 0.119 |
 Fibrates | 7.2 | 85.3 | 810.5 | 48.0 | 26.7 | 0.530 |